...
首页> 外文期刊>Japanese Journal of Pharmacology >From Molecular Structure to Alzheimer Therapy
【24h】

From Molecular Structure to Alzheimer Therapy

机译:从分子结构到阿兹海默疗法

获取原文

摘要

References(87) Cited-By(47) Clinical trials in the USA, Japan and Europe have confirmed the hypothesis that a steady state increase of acetylcholine resulting from cholinesterase inhibition in the brain results in an improvement of cognitive function in mild to moderate Alzheimer disease (AD)patients. During the last decade, a systematic effort to develop a pharmacological treatment for AD has resulted in two drugs being registered for the first time in the USA and Europe for this specific indication. Both are cholinesterase inhibitors (ChEI). Based on these first positive results, several second generation ChEI are being developed. An additional effect of certain ChEI is to maintain cognitive function at a constant level during a 6 months to one year period of treatment as compared to placebo. It is possible that the drug effect is one of slowing down cognitive deterioration. Comparison of clinical effects of 5 ChEI demonstrates a rather similar magnitude of improvement. For some drugs, this may represent a limit, while for others it may be possible to increase the benefit further. To maximize and prolong positive drug effects, it is important to start early and adjust the dosage during the treatment. Other strategies may involve combinations with other cholinergic drugs such as muscarinic or nicotinic agonists. A second important class of drugs which is being developed is that of muscarinic ml agonists. However, their clinical use is still limited by side effects. The increased knowledge and recognition of the beta-amyloid molecule as a central focus of AD pathology has strongly stimulated research with the hope of finding ways of influencing its processing and deposition. At this point, no product in this line of development has reached clinical trial level. Other pharmacological approaches are related to preventive and neuroprotective interventions (estrogens, anti-oxidants and anti-inflammatories). In conclusion, given the relatively short time of research in this field, results are encouraging.
机译:参考文献(87)被Cyed-By(47)在美国,日本和欧洲的临床试验证实了以下假设:大脑中胆碱酯酶抑制引起的乙酰胆碱稳态增加导致轻度至中度阿尔茨海默氏病的认知功能改善(AD)病人。在过去的十年中,为开发用于AD的药物疗法的系统性努力已导致针对该特定适应症在美国和欧洲首次注册了两种药物。两者都是胆碱酯酶抑制剂(ChEI)。基于这些最初的积极成果,正在开发几种第二代ChEI。与安慰剂相比,某些ChEI的另一个作用是在6个月至一年的治疗期间将认知功能维持在恒定水平。药物作用可能是减缓认知退化的一种。比较5种ChEI的临床效果,显示出相当相似的改善幅度。对于某些药物,这可能是一个限制,而对于另一些药物,则可能会进一步增加收益。为了最大化和延长药物的积极作用,在治疗期间及早开始并调整剂量很重要。其他策略可能涉及与其他胆碱能药物(例如毒蕈碱或烟碱激动剂)联合使用。正在开发的第二类重要药物是毒蕈碱ml激动剂。但是,它们的临床应用仍然受到副作用的限制。对β-淀粉样蛋白分子作为AD病理学的中心焦点的认识和认可的增加,极大地刺激了研究,希望找到影响其加工和沉积的方法。在这一点上,这一开发领域的产品还没有达到临床试验水平。其他药理方法与预防和神经保护性干预措施(雌激素,抗氧化剂和抗炎药)有关。总之,鉴于该领域的研究时间相对较短,结果令人鼓舞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号